Measurement of urinary chemokine and growth factor messenger RNAs: A noninvasive monitoring in lupus nephritis

Kidney International

Volumn 69, Issue 4, 2006, Pages 747-753

  Avihingsanon, Y ^a   Phumesin, P ^a   Benjachat, T ^a   Akkasilpa, S ^a   Kittikowit, V ^a   Praditpornsilpa, K ^a   Wongpiyabavorn, J ^a   Eiam Ong, S ^a   Hemachudha, T ^a   Tungsanga, K ^a   Hirankarn, N ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Chemokine; Growth factor; Interferon producing protein 10; Lupus nephritis; Transforming growth factor ; Vascular endothelial growth factor

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MONITORING; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STANDARDIZATION; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; URINALYSIS;

ADULT; BIOLOGICAL MARKERS; CHEMOKINES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION; GROWTH SUBSTANCES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; LUPUS NEPHRITIS; MALE; PYRIMIDINONES; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; THIAZOLES; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 32544449674     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000132     Document Type: Article

References (30)

1. Ponticelli C. Treatment of lupus nephritis - the advantages of a flexible approach. Nephrol Dial Transplant 1997; 12: 2057-2059.
2. Houssiau FA. Management of lupus nephritis: an update. J Am Soc Nephrol 2004; 15: 2694-2704.
3. Ponticelli C, Moroni G. Flares in lupus nephritis: incidence, impact on renal survival and management. Lupus 1998; 7: 635-638.
4. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999; 10: 413-424.
5. El Hachmi M, Jadoul M, Lefebvre C et al. Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus 2003; 12: 692-696.
6. Moroni G, Pasquali S, Quaglini S et al. Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis 1999; 34: 530-539.
7. Wenzel J, Worenkamper E, Freutel S et al. Enhanced type I interferon signalling promotes Th I-biased inflammation in cutaneous lupus erythematosus. J Pathol 2005; 205: 435-442.
8. Shiozawa F, Tsuyoshi K, Nobuyuki Y et al. Enhanced expression of interferon-inducible protein 10 associated with Th1 profiles of chemokine receptor in autoimmune pulmonary inflammation of MRL/lprmice. Arthritis Res Ther 2004; 6: R78-R86.
9. Hancock WW, Lu B, Gao W et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000; 192: 1515-1520.
10. Rovin BH. Chemokine blockade as a therapy for renal disease (review). Curr Opin Nephrol Hyper 2000; 9: 225-232.
11. Narumi S, Takeuchi T, Kobayashi Y, Konishi K. Serum levels of ifn-inducible protein-10 relating to the activity of systemic lupus erythematosus. Cytokine 2000; 12: 1561-1565.
12. Chan RW, Tam LS, Li EK et al. Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 2003; 48: 1326-1331.
13. Chan RW, Lai FM, Li EK et al. Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 2004; 50: 2882-2890.
14. Grande JP. Mechanisms of progression of renal damage in lupus nephritis: pathogenesis of renal scarring. Lupus 1998; 7: 604-610.
15. Perez de Lema G, Maier H, Nieto E et al. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol 2001; 12: 1369-1382.
16. Aten J, Roos A, Claessen N et al. Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol 2000; 11: 1426-1438.
17. Kitamura S, Maeshima Y, Sugaya T et al. Transforming growth factor-beta 1 induces vascular endothelial growth factor expression in murine proximal tubular epithelial cells. Nephron Exp Nephrol 2003; 95: e79-e86.
18. Pintavorn P, Ballermann BJ. TGF-beta and the endothelium during immune injury. Kidney Int 1997; 51: 1401-1412.
19. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003-2017.
20. Navarro C, Candia-Zuniga L, Silveira LH et al. Vascular endothelial growth factor plasma levels in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Lupus 2002; 11: 21-24.
21. Li BH, Ding R, Sharma VK et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perform and granzyme B in urine. N Engl J Med 2001; 344: 947-954.
22. Gourley MF, Austin III HA, Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med 1996; 125: 549-557.
23. Chan TM, Li FK, Tang CSO et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-1162.
24. Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-2131.
25. Eikmans M, Baelde HJ, Hagen EC et al. Renal mRNA levels as prognostic tools in kidney diseases. J Am Soc Nephrol 2003; 14: 899-907.
26. Rovin BH, Song H, Birmingham DJ et al. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 2005; 16: 467-473.
27. Austin HA, Muenz LR, Joyce KM et al. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689-695.
28. Appel GB, Radhakrishnan J, D'Agati VD. Secondary glomerular disease. In: Brenner BM (ed). The Kidney, 7th edn, vol. 1. Saunders: Philadelphia, 2004, pp 1381-1481.
29. Boumpas DT, Balow JE. Outcome criteria for lupus nephritis trials: a critical overview. Lupus 1998; 7: 622-629.
30. Grande JP, Balow JE. Renal biopsy in lupus nephritis. Lupus 1998; 7: 611-617.